Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells

(2014) A. A. El-Mabhouh et al.   BLOOD

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects inTP53

(2014) Polina Shindiapina et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells

(2014) J. C. Godbersen et al.   CLINICAL CANCER RESEARCH

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles’ heel in mantle cell lymphoma

(2014) M A Dengler et al.   Cell Death & Disease

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells

(2013) M. F. Pascutti et al.   BLOOD

Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia

(2013) Leigh A. Humphries et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bcl2 Induces DNA Replication Stress by Inhibiting Ribonucleotide Reductase

(2013) M. Xie et al.   CANCER RESEARCH

Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts

(2013) Alexey V Danilov et al.   Expert Review of Anticancer Therapy

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

(2012) M. S. Davids et al.   BLOOD

Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924

(2012) J. L. Blank et al.   CANCER RESEARCH

Re-replication induced by geminin depletion occurs from G2 and is enhanced by checkpoint activation

(2012) K. Klotz-Noack et al.   JOURNAL OF CELL SCIENCE

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2012) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents

(2012) Y. Kee et al.   MOLECULAR CANCER RESEARCH

WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

(2012) C Mackintosh et al.   ONCOGENE

The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme

(2012) Dong Yang et al.   PLoS One

Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis

(2012) Y Zhao et al.   Cell Death & Disease

Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor

(2011) D. Wei et al.   CANCER RESEARCH

Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover

(2011) M. A. Milhollen et al.   CANCER RESEARCH

Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease

(2011) Robert C. Rickert et al.   IMMUNOLOGICAL REVIEWS

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2011) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells

(2010) J. J. Lin et al.   CANCER RESEARCH

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

(2010) J M Tromp et al.   ONCOGENE

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

(2009) J. A. Burger et al.   BLOOD

Bendamustine: Rebirth of an Old Drug

(2009) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

(2008) A. Gowda et al.   BLOOD

Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

(2008) G. Roue et al.   CLINICAL CANCER RESEARCH

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH